Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
SCHOTT Group's updated climate targets, including the business scope of SCHOTT Pharma, have been validated by the Science Based Targets initiative (SBTi). The company continues to focus on sourcing Energy Attribute Certificates from renewable ene...
Schott Pharma AG & CO KGaA (WBO:1SXP) reports 8.3% constant-currency revenue growth in Q3, lifts full-year outlook, and secures a key take-or-pay glass syringe agreement.
LEBANON, Pa., June 03, 2026--SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs – from biologics and other complex injectable therapies to vaccines and emergency room medications. The new capabilities feature state-of-the-art technology for efficient manufacturing and optimized output. The over 60 million USD investment was largely fu
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...
Despite headwinds in the DDS segment, Schott Pharma AG & CO KGaA (WBO:1SXP) maintains growth momentum and confirms full-year guidance.
While SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) might not have the largest market cap around , it saw a significant...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.